Cargando…

Clinical Management of HIV Drug Resistance

Combination antiretroviral therapy for HIV-1 infection has resulted in profound reductions in viremia and is associated with marked improvements in morbidity and mortality. Therapy is not curative, however, and prolonged therapy is complicated by drug toxicity and the emergence of drug resistance. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortez, Karoll J., Maldarelli, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185705/
https://www.ncbi.nlm.nih.gov/pubmed/21994737
http://dx.doi.org/10.3390/v3040347
_version_ 1782213251555131392
author Cortez, Karoll J.
Maldarelli, Frank
author_facet Cortez, Karoll J.
Maldarelli, Frank
author_sort Cortez, Karoll J.
collection PubMed
description Combination antiretroviral therapy for HIV-1 infection has resulted in profound reductions in viremia and is associated with marked improvements in morbidity and mortality. Therapy is not curative, however, and prolonged therapy is complicated by drug toxicity and the emergence of drug resistance. Management of clinical drug resistance requires in depth evaluation, and includes extensive history, physical examination and laboratory studies. Appropriate use of resistance testing provides valuable information useful in constructing regimens for treatment-experienced individuals with viremia during therapy. This review outlines the emergence of drug resistance in vivo, and describes clinical evaluation and therapeutic options of the individual with rebound viremia during therapy.
format Online
Article
Text
id pubmed-3185705
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Molecular Diversity Preservation International (MDPI)
record_format MEDLINE/PubMed
spelling pubmed-31857052011-10-12 Clinical Management of HIV Drug Resistance Cortez, Karoll J. Maldarelli, Frank Viruses Review Combination antiretroviral therapy for HIV-1 infection has resulted in profound reductions in viremia and is associated with marked improvements in morbidity and mortality. Therapy is not curative, however, and prolonged therapy is complicated by drug toxicity and the emergence of drug resistance. Management of clinical drug resistance requires in depth evaluation, and includes extensive history, physical examination and laboratory studies. Appropriate use of resistance testing provides valuable information useful in constructing regimens for treatment-experienced individuals with viremia during therapy. This review outlines the emergence of drug resistance in vivo, and describes clinical evaluation and therapeutic options of the individual with rebound viremia during therapy. Molecular Diversity Preservation International (MDPI) 2011-04-14 /pmc/articles/PMC3185705/ /pubmed/21994737 http://dx.doi.org/10.3390/v3040347 Text en © 2011 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0 This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Cortez, Karoll J.
Maldarelli, Frank
Clinical Management of HIV Drug Resistance
title Clinical Management of HIV Drug Resistance
title_full Clinical Management of HIV Drug Resistance
title_fullStr Clinical Management of HIV Drug Resistance
title_full_unstemmed Clinical Management of HIV Drug Resistance
title_short Clinical Management of HIV Drug Resistance
title_sort clinical management of hiv drug resistance
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185705/
https://www.ncbi.nlm.nih.gov/pubmed/21994737
http://dx.doi.org/10.3390/v3040347
work_keys_str_mv AT cortezkarollj clinicalmanagementofhivdrugresistance
AT maldarellifrank clinicalmanagementofhivdrugresistance